Yes_老虎社区_美港股上老虎

Baijiaomau
2021-11-26

Yes

Cannabis-Focused Biotech Company Can-Fite Reports Q3 Financial Results & Clinical Updates

Cannabis-focused biotech company Can-Fite BioPharma Ltd. (AMEX: CANF) (TASE: CFBI) reported its financial results Friday for nine months ended September 30, 2021, with revenues of $650,000, compared to $610,000 in the same period of 2020.

Cannabis-Focused Biotech Company Can-Fite Reports Q3 Financial Results & Clinical Updates

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":877217373,"tweetId":"877217373","gmtCreate":1637935462389,"gmtModify":1637935462389,"author":{"id":3586944960680773,"idStr":"3586944960680773","authorId":3586944960680773,"authorIdStr":"3586944960680773","name":"Baijiaomau","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":6,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Yes</p></body></html>","htmlText":"<html><head></head><body><p>Yes</p></body></html>","text":"Yes","highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/877217373","repostId":2186281348,"repostType":4,"repost":{"id":"2186281348","kind":"highlight","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1637934348,"share":"https://www.laohu8.com/m/news/2186281348?lang=&edition=full","pubTime":"2021-11-26 21:45","market":"us","language":"en","title":"Cannabis-Focused Biotech Company Can-Fite Reports Q3 Financial Results & Clinical Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2186281348","media":"Benzinga","summary":"Cannabis-focused biotech company Can-Fite BioPharma Ltd. (AMEX: CANF) (TASE: CFBI) reported its financial results Friday for nine months ended September 30, 2021, with revenues of $650,000, compared to $610,000 in the same period of 2020.","content":"<p>Cannabis-focused biotech company<b> Can-Fite BioPharma Ltd.</b> (AMEX:CANF) (TASE: CFBI) reported its financial results Friday&nbsp;for nine months ended September 30, 2021,&nbsp;<b>with revenues of $650,000, compared to $610,000 in the same period of 2020</b>. Based in&nbsp;Petach Tikva, Israel, the&nbsp;company noted that the increase in revenue could be considered immaterial.</p>\n<h3><b>Financial Results For The Nine-Month Period Summary </b></h3>\n<ul>\n <li><b>Research and development expenses were $6.75 million</b> compared with $9.06 million for the same period in 2020;</li>\n <li><b>Net loss amounted to $8.49 million</b> or $0.02 per basic and diluted share, compared to the net loss of $10.81 million or $0.04 loss per share for the same period year ago;</li>\n <li>General and administrative expenses were $2.71 million, versus $2.14 million for the same period in the previous year;</li>\n <li>At the end of the reporting period on Sep. 30, 2021, Can-Fite <b>had $13.3 million in cash and cash equivalents,</b> compared to $8.16 million it held on Dec. 31, 2020.</li>\n</ul>\n<h3><b>Corporate And Clinical Development Highlights </b></h3>\n<ul>\n <li>Completed Patient Enrollment in Phase III Psoriasis Study – The Phase III Comfort™ study completed patient enrollment. Topline results are expected in Q1 2022;</li>\n <li>Can-Fite Ends Phase II COVID-19 Trial to Focus on Core Indications - In 2020, with the aim of developing a much-needed drug to treat manifestations of COVID-19, mainly the Cytokine Release Syndrome, Can-Fite initiated a Phase II COVID-19 study of its lead drug candidate, Piclidenoson, with patient enrollment in Israel and Europe.</li>\n <li>Patents Granted for NASH in Japan, Hong Kong&nbsp;and Mexico;</li>\n <li>Data on A3AR-based Cannabis Compounds in the Treatment of Liver Diseases Presented at AASLD and Published in HEPATOLOGY;</li>\n <li>Positive Phase IIa NASH Data Published in Alimentary Pharmacology &amp; Therapeutics;</li>\n</ul>\n<p>“Our NASH program has received a high level of interest at scientific conferences based on our positive Phase IIa results, and we continue to fortify our IP around this indication,” Can-Fite CEO Dr. <b>Pnina Fishman</b> stated. “We expect to commence enrollment in our pivotal Phase III liver cancer and Phase IIb NASH studies, as we look forward to topline results from our Phase III in psoriasis in the first quarter of 2022. Our advanced pipeline with a growing body of safety and efficacy data has significant potential to help patients with unmet needs.”</p>\n<p><b>Price Action </b></p>\n<p>Can-Fite’s shares<b> traded 1.64% higher at $1.2 per share during Friday’s pre-market session. </b></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cannabis-Focused Biotech Company Can-Fite Reports Q3 Financial Results & Clinical Updates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCannabis-Focused Biotech Company Can-Fite Reports Q3 Financial Results & Clinical Updates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-11-26 21:45</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Cannabis-focused biotech company<b> Can-Fite BioPharma Ltd.</b> (AMEX:CANF) (TASE: CFBI) reported its financial results Friday&nbsp;for nine months ended September 30, 2021,&nbsp;<b>with revenues of $650,000, compared to $610,000 in the same period of 2020</b>. Based in&nbsp;Petach Tikva, Israel, the&nbsp;company noted that the increase in revenue could be considered immaterial.</p>\n<h3><b>Financial Results For The Nine-Month Period Summary </b></h3>\n<ul>\n <li><b>Research and development expenses were $6.75 million</b> compared with $9.06 million for the same period in 2020;</li>\n <li><b>Net loss amounted to $8.49 million</b> or $0.02 per basic and diluted share, compared to the net loss of $10.81 million or $0.04 loss per share for the same period year ago;</li>\n <li>General and administrative expenses were $2.71 million, versus $2.14 million for the same period in the previous year;</li>\n <li>At the end of the reporting period on Sep. 30, 2021, Can-Fite <b>had $13.3 million in cash and cash equivalents,</b> compared to $8.16 million it held on Dec. 31, 2020.</li>\n</ul>\n<h3><b>Corporate And Clinical Development Highlights </b></h3>\n<ul>\n <li>Completed Patient Enrollment in Phase III Psoriasis Study – The Phase III Comfort™ study completed patient enrollment. Topline results are expected in Q1 2022;</li>\n <li>Can-Fite Ends Phase II COVID-19 Trial to Focus on Core Indications - In 2020, with the aim of developing a much-needed drug to treat manifestations of COVID-19, mainly the Cytokine Release Syndrome, Can-Fite initiated a Phase II COVID-19 study of its lead drug candidate, Piclidenoson, with patient enrollment in Israel and Europe.</li>\n <li>Patents Granted for NASH in Japan, Hong Kong&nbsp;and Mexico;</li>\n <li>Data on A3AR-based Cannabis Compounds in the Treatment of Liver Diseases Presented at AASLD and Published in HEPATOLOGY;</li>\n <li>Positive Phase IIa NASH Data Published in Alimentary Pharmacology &amp; Therapeutics;</li>\n</ul>\n<p>“Our NASH program has received a high level of interest at scientific conferences based on our positive Phase IIa results, and we continue to fortify our IP around this indication,” Can-Fite CEO Dr. <b>Pnina Fishman</b> stated. “We expect to commence enrollment in our pivotal Phase III liver cancer and Phase IIb NASH studies, as we look forward to topline results from our Phase III in psoriasis in the first quarter of 2022. Our advanced pipeline with a growing body of safety and efficacy data has significant potential to help patients with unmet needs.”</p>\n<p><b>Price Action </b></p>\n<p>Can-Fite’s shares<b> traded 1.64% higher at $1.2 per share during Friday’s pre-market session. </b></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4139":"生物科技","CANF":"Can-Fite Biopharma Ltd"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2186281348","content_text":"Cannabis-focused biotech company Can-Fite BioPharma Ltd. (AMEX:CANF) (TASE: CFBI) reported its financial results Friday for nine months ended September 30, 2021, with revenues of $650,000, compared to $610,000 in the same period of 2020. Based in Petach Tikva, Israel, the company noted that the increase in revenue could be considered immaterial.\nFinancial Results For The Nine-Month Period Summary \n\nResearch and development expenses were $6.75 million compared with $9.06 million for the same period in 2020;\nNet loss amounted to $8.49 million or $0.02 per basic and diluted share, compared to the net loss of $10.81 million or $0.04 loss per share for the same period year ago;\nGeneral and administrative expenses were $2.71 million, versus $2.14 million for the same period in the previous year;\nAt the end of the reporting period on Sep. 30, 2021, Can-Fite had $13.3 million in cash and cash equivalents, compared to $8.16 million it held on Dec. 31, 2020.\n\nCorporate And Clinical Development Highlights \n\nCompleted Patient Enrollment in Phase III Psoriasis Study – The Phase III Comfort™ study completed patient enrollment. Topline results are expected in Q1 2022;\nCan-Fite Ends Phase II COVID-19 Trial to Focus on Core Indications - In 2020, with the aim of developing a much-needed drug to treat manifestations of COVID-19, mainly the Cytokine Release Syndrome, Can-Fite initiated a Phase II COVID-19 study of its lead drug candidate, Piclidenoson, with patient enrollment in Israel and Europe.\nPatents Granted for NASH in Japan, Hong Kong and Mexico;\nData on A3AR-based Cannabis Compounds in the Treatment of Liver Diseases Presented at AASLD and Published in HEPATOLOGY;\nPositive Phase IIa NASH Data Published in Alimentary Pharmacology & Therapeutics;\n\n“Our NASH program has received a high level of interest at scientific conferences based on our positive Phase IIa results, and we continue to fortify our IP around this indication,” Can-Fite CEO Dr. Pnina Fishman stated. “We expect to commence enrollment in our pivotal Phase III liver cancer and Phase IIb NASH studies, as we look forward to topline results from our Phase III in psoriasis in the first quarter of 2022. Our advanced pipeline with a growing body of safety and efficacy data has significant potential to help patients with unmet needs.”\nPrice Action \nCan-Fite’s shares traded 1.64% higher at $1.2 per share during Friday’s pre-market session.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1032,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":3,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}